David Wainer is a Columnist at various outlets including The Wall Street Journal and Yahoo Finance. He covers a range of topics with a focus on medicine and healthcare, particularly healthcare technology, as well as finance and the food and beverages industry. David's insights have been featured in prominent publications such as LiveMint, Yahoo News, and RealClearMarkets.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
David Wainer's coverage predominantly focuses on investment analysis within the healthcare and pharmaceutical sectors. His articles encompass a range of topics, including stocks, biotech, and investing in relation to developments within these industries.
Given his focus on investment analysis and citation of data, David would likely be interested in receiving pitches from experts who can provide insightful perspectives backed by data related to healthcare and pharmaceutical companies' performance or industry trends. Additionally, professionals with expertise in financial analysis specific to the healthcare sector may find success when reaching out to him.
Considering his concentration on the international market rather than a specific geographic area, sources providing global insights into healthcare investments and pharmaceutical developments could capture his attention effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: J. Sébastien Gittens, Morgan Sutherland, Suzie Suliman, David Wainer, Kees de Ridder, Stephen Burns, Caroline Poirier, Ruth Promislow
Our lawyers were recently featured in the Canadian Privacy Law Review in an article that provides a high-level comparison of Canada’s key private-sector privacy regimes.
Oura pitched itself as a tech platform, but investors saw through that.
Oura's glossy smart ring is everywhere these days: in high-profile TV ad campaigns and on the fingers of plenty of people.
By: David Wainer
For the lodging platform’s stock to thrive in the age of bots, it has to turn repeat customers into loyal ones.
The problem may be bigger than a few weak brands. Pepsi needs to stop tinkering and consider more fundamental changes.
PepsiCo used to embody everything investors prized in a stock: dependable brands, reliable earnings growth and steady returns.
By: David Wainer
Healthcare stocks no longer trade at a discount to the broader market. That isn't a reason to sell.
By: David Wainer
The sector is trading at a premium as investors seek safety from AI jitters.
Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.
Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.
